<DOC>
	<DOCNO>NCT00575419</DOCNO>
	<brief_summary>This randomized prospective dose escalation clinical study N-acetylcysteine ( NAC ) patient stage 3 bad renal failure ( Glomerular Filtration Rate 30-60 ml/min calculate Modification Diet Renal Disease formula ) , undergoing procedure image require administration contrast medium Oregon Health &amp; Science University Portland Veterans Hospital . Subjects receive NAC 60 minute prior procedure image require contrast medium . Toxicity grade accord NCI Common Toxicity Criteria ( CTC ) version 3.0 . An adult Phase 1 dose escalation study NAC administer intravenously ( IV ) intra-arterially ( IA ) perform . An isotonic nonionic contrast agent use case . Contrast Induced Nephropathy ( CIN ) define increase serum creatinine concentration 25 % subject baseline value within 72-hour period administration contrast medium . Serum creatinine concentration measure admission , every day in-patient hospitalization , hospital discharge .</brief_summary>
	<brief_title>Safety Study Of N-Acetylcysteine For Prevention Of Contrast Induced Nephropathy In Patients w/Stage 3 Renal Failure</brief_title>
	<detailed_description>Radiographic contrast medium use increase rate various diagnostic therapeutic procedure . Renal failure follow contrast administration enhance image become serious complication . Patients underlie renal disorder increase incidence Contrast Induced Nephropathy ( CIN ) . CIN report third common cause in-hospital renal failure hypovolemia post surgical renal insufficiency . Several factor increase risk CIN : preexist renal dysfunction , volume type contrast agent employ , lack renal prophylaxis . CIN pathogenesis may due injury renal cortex outer medulla result decrease blood flow , osmotic effect , and/or direct toxicity tubular cell oxygen free radical . N-acetylcysteine ( NAC ) cysteine analog sulfur-containing agent , strong antioxidant activity , induces de novo synthesis glutathione . NAC protection evolution renal failure may relate ability scavenge oxygen free radical and/or improve endothelium-dependant vasodilation . There animal model directly correlate CIN , investigator investigate nephrotoxicity chemoprotection cisplatin induce nephropathy mechanism action mediate generation reactive intermediate animal model . NAC potentially protective cisplatin induced nephrotoxicity administer high intravenous ( IV ) dose ( 400 mg/kg ) low intra-arterial ( IA ) dose ( 50mg/kg ) descend aorta . This imply safe dose-dependent effect IV NAC low dos use IA safely . Objectives : Primary Objective : The primary objective study establish maximum tolerate dose IV IA NAC . This maximum tolerate dose evaluate primarily efficacy future study . Secondary Objectives : 1 . To obtain data change baseline serum creatinine calculate creatinine clearance provide sample size estimate future study . 2 . To estimate efficacy NAC reduce incidence CIN . While study adequately power address objective , analysis run assess increase serum creatinine concentration 25 % baseline value within 48-72 hour period procedure image require administration contrast medium surrogate CIN incidence . 3 . To determine NAC pharmacology administer IV IA .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Renal failure , stage 3 bad Undergoing endovascular procedure isotonic , non ionize contrast agent Life expectancy least 4 week date registration Platelets great equal 100,000/mm3 Systolic pressure great 90 mm Hg No contraindication NAc contrast agent Not risk general anesthesia Acute renal failure Undergoing dialysis Decompensate cardiac failure Pregnant nursing History clinically significant reactive airway disease Receiving nonsteroidal antiinflammatory agent within 24 hour study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Contrast Induced Nephropathy</keyword>
</DOC>